Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: risk factors for morbidity and postoperative outcome.
CONCLUSIONS: The risks of perioperative morbidity and mortality after CRS and HIPEC are analogous to any other major gastrointestinal surgery. CRS and HIPEC should remain a treatment option for highly selected patients in whom a curative or life prolonging treatment is a pursuit and should be performed in high volume specialized institutions.
PMID: 29589675 [PubMed - as supplied by publisher]
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Epithelial Cancer | Gastroenterology | Mesothelioma | Ovarian Cancer | Ovaries | Peritoneal Cancer | Statistics | Surgery